Combination therapy as a potential strategy in Glioblastoma treatment

Kattner, Patricia; Nonnenmacher, Lisa; Buljovcic, K; Bartholomä, S; Zeiler, Katharina; Karpel‐Massler, Georg; Halatsch, ME; Westhoff, Mike‐Andrew; Debatin, KM

doi:10.1055/s-0038-1675273

27th Annual Meeting of the Working Group “Experimental Neuro-Oncology” 2018

DOI: 10.1055/s-0038-1675273

|View full text |Cite

Combination therapy as a potential strategy in Glioblastoma treatment

Patricia Kattner

Lisa Nonnenmacher

K Buljovcic

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5,6 Various chemotherapies combined with surgery and radiotherapy have been developed to treat the recurrence of glioblastoma. [7][8][9] Temozolomide, an oral second-generation alkylating agent, demonstrated some antineoplastic activity. 10,11 Temozolomide was reported to show some benefits to treat patients with glioblastoma recurrence and treatment failure by other therapies.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Adjuvant Temozolomide for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies

Zhao¹,

Shi³

2021

Clin Neuropharm

View full text Add to dashboard Cite

Introduction The efficacy of adjuvant temozolomide to radiotherapy for glioblastoma remained elusive. This meta-analysis aimed to explore the influence of radiotherapy plus adjuvant temozolomide on the efficacy and safety for glioblastoma. Methods We have searched several databases including PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through November 2020 and included randomized controlled trials assessing the efficacy and safety of adjuvant temozolomide to radiotherapy for glioblastoma. Results Seven randomized controlled trials and 1900 patients were included in the meta-analysis. Overall, compared with radiotherapy for glioblastoma, adjuvant temozolomide was associated with significantly increased survival rate [odds ratio (OR), 4.04; 95% confidence interval (CI), 2.61–6.24; P < 0.00001], median progression-free survival (mean difference, 0.55; 95% CI, 0.03–1.07; P = 0.04), and hematological complications (OR, 4.12; 95% CI, 1.43–11.88; P = 0.009), but revealed no remarkable influence on adverse events (OR, 0.87; 95% CI, 0.36–2.09; P = 0.75) or serious adverse events (OR, 2.20; 95% CI, 0.55–8.70; P = 0.26). Conclusions Adjuvant temozolomide in combination with radiotherapy may improve the treatment efficacy for glioblastoma.

show abstract

mentioning

confidence: 99%

“…Various chemotherapies combined with surgery and radiotherapy have been developed to treat the recurrence of glioblastoma 7–9 . Temozolomide, an oral second-generation alkylating agent, demonstrated some antineoplastic activity 10,11 .…”

mentioning

confidence: 99%

Adjuvant Temozolomide for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies

Zhao¹,

Shi³

2021

Clin Neuropharm

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Combination therapy as a potential strategy in Glioblastoma treatment

Cited by 1 publication

References 0 publications

Adjuvant Temozolomide for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies

Adjuvant Temozolomide for the Treatment of Glioblastoma: A Meta-analysis of Randomized Controlled Studies

Contact Info

Product

Resources

About